VISTA Eye Specialists works with Tzu Chi Malaysia to Help Restore Eyesight with 100 Charity Cataract Surgery
PETALING JAYA, Malaysia, Feb. 21, 2022 /PRNewswire/ -- In conjunction with World Sight Day 2021, VISTA Eye Specialist (VISTA) is continuing to support the fight towards eliminating preventable blindness by pledging to provide 100 Charity Cataract surgeries via a joint community service project with Tzu Chi Malaysia in improving the quality of life of the affected individuals and their...
Action for bone health is needed now more than ever, urges IOF
NYON, Switzerland, Oct. 20, 2021 /PRNewswire/ -- A backlog in osteoporosis assessments, treatment delays, and sedentary indoor lifestyles: these are just several ways in which the Covid-19 pandemic has impacted bone health and disrupted global osteoporosis care. Osteoporosis is a common bone disorder that leads to weak and fragile bones which fracture easily. An osteoporotic fracture typically occurs as...
Wellspring Capital Management Acquires Caring Brands International
SUNRISE, Fla., Oct. 25, 2021 /PRNewswire/ -- Wellspring Capital Management ("Wellspring"), a leading private equity firm headquartered in New York, announced today that it has partnered with management to complete the acquisition of Caring Brands International, Inc. ("CBI" or the "Company"). Terms of the transaction were not disclosed. Tracing its heritage back to 1966, CBI is the leading franchisor...
TurtleTree Raises US$30 Million in First Tranche of Series A Funding
SAN FRANCISCO, Calif., and SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- TurtleTree has successfully raised US$30 million in the first tranche of their Series A funding, one of the largest investment rounds to date in Asia's cell-based food sector. Rapidly gaining prominence for its novel use of cell-based technology in milk production, the biotech company has now secured fresh funding from...
UAE to receive award from Parliamentary Assembly of the Mediterranean for Waterfalls Initiative
ROME, Nov. 19, 2021 /PRNewswire/ -- On Thursday November 18, in the Sala Protomoteca of the Campidoglio in Rome, the United Arab Emirates, represented by Saif bin Zayed, Deputy Prime Minister and Minister of the Interior received an award from the Parliamentary Assembly of the Mediterranean (PAM) for Waterfalls, a global initiative launched by the UAE Ministry of Possibilities,...
Rayence’s Low-Dose Detector “GreenON” Receives Critical Acclaim at RSNA 2021
SEOUL, South Korea, Dec. 2, 2021 /PRNewswire/ -- Rayence(www.rayence.com) reported that its low-dose detectors "GreenON" received critical acclaim at the RSNA(Radiological Society of North America) 2021. Rayence at RSNA 2021 At the conference, Rayence exhibited a portfolio of products built on its proprietary low-dose technology, including x-ray detectors and software solutions, under the slogan "Better Dose for...
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18
BEIJING and BRIDGEWATER, N.J., Dec. 7, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to improve the management of type 2 diabetes mellitus....
Akeso’s PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA
HONG KONG, Dec. 23, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd., completed patient enrollment early in a pivotal registrational phase III clinical trial in the People's Republic of China for the treatment of primary hypercholesterolemia and...
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
Establishment of Joint Venture Company named SanPlena in the US Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. Sir Stephen Bloom, world-renowned researcher in the field of obesity and metabolism at Imperial College London (UK) 10-15% weight loss in 2-3 months eyed with...
Seegene Announces Q4 and Full-Year 2021 Financial Results
Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY Q4 Revenue of KRW 410 billion, up 34% QoQ Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D Seegene to make a strategic shift to a 'molecular...
